Kamada Ltd. (NASDAQ:KMDA) Sees Significant Growth in Short Interest

Kamada Ltd. (NASDAQ:KMDA) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 56,800 shares, an increase of 61.8% from the February 28th total of 35,100 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average trading volume of 210,800 shares, the days-to-cover ratio is currently 0.3 days.

Kamada Stock Down 1.2 %

Shares of NASDAQ KMDA traded down $0.08 during midday trading on Friday, reaching $6.75. The company had a trading volume of 49,625 shares, compared to its average volume of 79,188. The firm’s fifty day moving average price is $7.17 and its 200-day moving average price is $6.32. Kamada has a one year low of $4.74 and a one year high of $9.16. The stock has a market cap of $387.99 million, a PE ratio of 24.11, a price-to-earnings-growth ratio of 0.97 and a beta of 0.97.

Kamada Dividend Announcement

The company also recently announced a — dividend, which will be paid on Monday, April 7th. Stockholders of record on Monday, March 17th will be issued a $0.20 dividend. The ex-dividend date is Monday, March 17th.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. StockNews.com lowered Kamada from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, March 25th. HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of Kamada in a report on Thursday, March 6th. Finally, Benchmark assumed coverage on Kamada in a research note on Friday, March 21st. They set a “buy” rating and a $15.00 price target for the company.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. NewEdge Advisors LLC increased its position in shares of Kamada by 54.2% in the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after acquiring an additional 8,260 shares during the period. Aristides Capital LLC grew its stake in shares of Kamada by 12.1% in the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock worth $387,000 after purchasing an additional 6,850 shares during the last quarter. Geode Capital Management LLC increased its holdings in Kamada by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after purchasing an additional 1,549 shares during the period. JPMorgan Chase & Co. purchased a new stake in Kamada in the 4th quarter worth approximately $67,000. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Kamada in the 3rd quarter worth approximately $77,000. 20.38% of the stock is owned by hedge funds and other institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.